Palvella Therapeutics (PVLA) Change in Account Payables (2014 - 2026)
Palvella Therapeutics (PVLA) reported Change in Account Payables of $851000.0 for Q1 2026, down 24.29% year-over-year from $1.1 million in Q1 2025, and down 26.38% on a QoQ basis from $1.2 million in Q4 2025.
Palvella Therapeutics (PVLA) has 7 years of Change in Account Payables data on file, last reported at $851000.0 in Q1 2026.
- Quarterly Change in Account Payables fell 24.29% year-over-year to $851000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $987000.0 (down 69.88% YoY) and the FY2025 annual result came in at $1.3 million, down 43.7% from the prior year.
- Change in Account Payables declined to $851000.0 in Q1 2026 per PVLA's latest filing, from $1.2 million in the prior quarter.
- Across five years, Change in Account Payables topped out at $1.7 million in Q3 2024 and bottomed at -$1.1 million in Q3 2025.
- The 3-year median for Change in Account Payables is $425000.0 (2024), against an average of $483222.2.
- Peak annual rise in Change in Account Payables reached 2588.37% in 2025, while the deepest fall reached 167.42% in 2025.
- Tracing PVLA's Change in Account Payables over 3 years: stood at $43000.0 in 2024, then jumped by 2588.37% to $1.2 million in 2025, then declined by 26.38% to $851000.0 in 2026.
- Per Business Quant, the three latest PVLA Change in Account Payables figures stand at $851000.0 (Q1 2026), $1.2 million (Q4 2025), and -$1.1 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -3.26 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 35.60 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Palvella Therapeutics | 1.47 Bn | 1.21 Bn | - | 851,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 851,000.00 |
| Mar 31, 2026 | 851,000.00 |
| Dec 31, 2025 | 1.16 Mn |
| Dec 31, 2025 | 1.16 Mn |
| Sep 30, 2025 | -1.14 Mn |
| Sep 30, 2025 | -1.14 Mn |
| Jun 30, 2025 | 116,000.00 |
| Jun 30, 2025 | 116,000.00 |
| Mar 31, 2025 | 1.12 Mn |
| Mar 31, 2025 | 1.12 Mn |
| Dec 31, 2024 | 43,000.00 |
| Dec 31, 2024 | 43,000.00 |
| Sep 30, 2024 | 1.69 Mn |
| Sep 30, 2024 | 1.69 Mn |
| Jun 30, 2024 | 425,000.00 |
| Jun 30, 2024 | 425,000.00 |
| Mar 31, 2024 | 85,000.00 |
| Mar 31, 2024 | 85,000.00 |
| Dec 31, 2017 | -186,768.00 |
| Dec 31, 2017 | -186,768.00 |
| Sep 30, 2017 | -2.13 Mn |
| Sep 30, 2017 | -2.13 Mn |
| Jun 30, 2017 | 1.72 Mn |
| Jun 30, 2017 | 1.72 Mn |
| Mar 31, 2017 | 263,025.00 |
| Mar 31, 2017 | 263,025.00 |
| Dec 31, 2016 | -1.94 Mn |
| Dec 31, 2016 | -1.94 Mn |
| Sep 30, 2016 | 2.95 Mn |
| Sep 30, 2016 | 2.95 Mn |
| Jun 30, 2016 | -246,647.00 |
| Jun 30, 2016 | -246,647.00 |
| Mar 31, 2016 | 597,189.00 |
| Mar 31, 2016 | 597,189.00 |
| Dec 31, 2015 | -41,497.00 |
| Dec 31, 2015 | -41,497.00 |
| Sep 30, 2015 | -946,557.00 |
| Sep 30, 2015 | -946,557.00 |
| Jun 30, 2015 | 456,481.00 |
| Jun 30, 2015 | 456,481.00 |
| Mar 31, 2015 | 440,649.00 |
| Mar 31, 2015 | 440,649.00 |
| Sep 30, 2014 | -3,324.00 |
| Sep 30, 2014 | -3,324.00 |
| Jun 30, 2014 | 487,595.00 |
| Jun 30, 2014 | 487,595.00 |
| Mar 31, 2014 | 370,122.00 |
| Mar 31, 2014 | 370,122.00 |